Why was the use of hydroxychloroquine and HIV medicine discontinued on corona-infected patients?

 05 Jul 2020 ( News Bureau )
POSTER

The World Health Organization said Saturday that hydroxychloroquine and lopinavir / ritonavir are being discontinued on corona-infected patients.

The hydroxychloroquine used to treat malaria and the lopinavir / ritonavir drug given to HIV patients did not succeed in preventing mortality of corona infectives, after which the decision has been taken.

The drug was seen as an expectation in different vaccine and medicine trials in search of treatment for corona and this bad news has come at a time when the World Health Organization itself has reported that for the first time worldwide More than two lakh corona infection cases have been reported in a single day.

On Friday, there were 212,326 reported cases of corona infection worldwide, with 53,213 cases reported in the US alone.

The World Health Organization said in a statement, "The results from the medical trial showed that the use of hydroxychloroquine and lopinavir / ritonavir reduced the mortality rate of hospitalized corona patients by little or no. Therefore, trial of these drugs will be stopped with immediate effect.

In different countries of the world, the effect of these drugs on corona patients under the leadership of the World Health Organization was being investigated.

The United Nations Health Agency said that the decision has been taken based on the recommendation of an international committee.

However, the WHO has clarified that patients who are not hospitalized and who use them as a preventive treatment will not be affected by this decision.

 

(Click here for Android APP of IBTN. You can follow us on facebook and Twitter)

Share This News

About sharing

Advertisement

https://www.ibtnkhabar.com/

 

https://www.ibtnkhabar.com/

Al Jazeera English | Live


https://www.ibtnkhabar.com/

https://www.ibtnkhabar.com/

https://www.ibtnkhabar.com/

https://www.ibtnkhabar.com/

https://www.ibtnkhabar.com/

Copyright © 2024 IBTN World All rights reserved. Powered by IBTN Media Network & IBTN Technology. The IBTN is not responsible for the content of external sites. Read about our approach to external linking